TAVR 单一闭合技术与双重闭合技术的比较 (Single)
使用单 Perclose 装置与双 Perclose 装置进行经股主动脉瓣置换术通路部位封闭：一项前瞻性、多中心、随机对照试验
Transcatheter aortic valve replacement (TAVR) has become widely recognized as a minimally invasive approach for aortic valve replacement in patients with severe aortic stenosis. It has been proven to be a safe and effective option for patients who are at low, intermediate, and prohibitive risk for surgical valve replacement.
One of the critical components of procedural success in a transfemoral approach is access site management, as vascular complications strongly correlate with adverse outcomes. When major vascular complications occur, there are higher rates of major bleeding, transfusions, and renal failure requiring dialysis, as well as a significantly higher rate of 30-day and 1-year mortality. In recent years, a "preclosure" technique has emerged as a common vascular closure approach using a Perclose Proglide system (Abbott Vascular), in which sutures are deployed before dilating the arterial access site. This allows for arterial closure after dilation to sizing up to larger bore access sheaths that accommodate valve delivery systems. The sutures are subsequently harvested and tightened to close the large bore arteriotomy site at the end of the case. It has been demonstrated that the use of two Perclose devices, or double Perclose closure, is an effective closure technique with a low rate of vascular complications. A large number of TAVR centers have adopted this method for large-bore vascular closure. In the past, there have been few investigations comparing the utilization of a single Perclose device compared to a double Perclose technique. There are numerous theoretical advantages to the use of a single device, which include decreased procedural cost and procedural time. The investigation aimed to determine if there are clinical benefits as well using the single Perclose approach.
研究概览
详细说明
SINGLE-CLOSURE (The utilization of Single versus double perclose devices for transfemoral aortIc valve replacement access site Closure) is an investigator-initiated, open-label, multicenter, randomized controlled trial. The study was approved by the local ethics committees of all participating centers, and each patient provided written informed consent for inclusion in the trial. Data management and analysis was performed by an independent data coordinating center, with oversight from a steering committee. The members of the steering committee had full access to the data and vouch for the accuracy and complete- ness of the data and the analyses. The data that support the findings of this study are available from the corresponding author on reasonable request. Patients scheduled to undergo transfemoral TAVR were considered for inclusion in the trial if they met all inclusion and none of the exclusion criteria. Inclusion criteria were an indication for TAVR as judged by the local heart team; selection of the transfemoral access route and a commercially available transcatheter aortic valve; and willingness to comply with protocol specified follow-up evaluations. Principal exclusion criteria were a vascular access site anatomy not suitable for percutaneous vascular closure and the occurrence of vascular access site complications before the TAVR procedure. Additional exclusion criteria were a known allergy or hypersensitivity to any VCD component; unstable active bleeding or bleeding diathesis or significant unman-ageable anemia; absence of computed tomographic data of the access site before the procedure; systemic infection or a local infection at or near the access site; life expectancy of <6 months because of noncardiac conditions; patients who cannot adhere to or complete the investigational protocol for any reason; pregnant or nursing patients; and participation in any other interventional trial.
The primary end point of the trial was the rate of access site or access-related major and minor vascular complications defined according to the Valve Academic Research Consortium-3 criteria. The end point was assessed during index hospitalization. Relationship to the access site was deter- mined according to the site used for the large-bore vascular access sheath.
Secondary end points included the rate of the primary end point at 30 days; components of the primary end point in-hospital and at 30 days; in-hospital and 30-day major and minor vascular complications; unplanned vascular surgery or use of endovascular stent or stent-graft or other endovascular interventions at the puncture site; in-hospital and 30-day access site- or access-related minor, major, and disabling or life threatening bleeding; need for blood transfusion for access site- or access-related bleeding or vascular complications; rate of VCD failure, defined as the failure of a closure device strategy to achieve hemostasis with the need for an alternative treatment (other than manual compression or adjunctive endovascular ballooning); in-hospital and 30-day all-cause death; in-hospital and 30-day death attributed to access site or access-related complications; need and number of additional unplanned VCDs; time to hemostasis, defined as the time from VCD application to complete hemostasis; and the length of postprocedural hospital stay.
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Beijing、中国
- Fuwai Hospital, Chinese Academy of Medical Sciences
-
Beijing、中国
- Beijing Anzhen Hospital, Capital Medical University
-
-
Anhui
-
Bengbu、Anhui、中国
- The First Affiliated Hospital of Bengbu Medical College
-
-
Fujian
-
Fuzhou、Fujian、中国
- Fujian Provincial Hospital
-
-
Gansu
-
Lanzhou、Gansu、中国
- The First Hospital of Lanzhou University
-
-
Guangdong
-
Guangzhou、Guangdong、中国
- The First Affiliated Hospital, Sun Yat-sen University
-
Guangzhou、Guangdong、中国
- Nanfang Hospital, Southern Medical University
-
Zhanjiang、Guangdong、中国
- The Affiliated Hospital of Guangdong Medical University
-
-
Guangxi
-
Yulin、Guangxi、中国
- Yulin First People's Hospital
-
-
Henan
-
Changshacun、Henan、中国
- Xiangya Hospital of Central South University
-
Zhengzhou、Henan、中国
- Fuwai Central China Cardiovascular Hospital
-
Zhengzhou、Henan、中国
- Henan Provincial Chest Hospital
-
-
Hunan
-
Changsha、Hunan、中国
- The Second Xiangya Hospital of Central South University
-
-
Liaoning
-
Shenyang、Liaoning、中国
- General Hospital of Northern Theater Command, PLA
-
-
Shandong
-
Jinan、Shandong、中国
- Qilu Hospital of Shandong University
-
Qingdao、Shandong、中国
- The Affiliated Hospital of Qingdao University
-
Qingdao、Shandong、中国
- Qingdao Municipal Hospital
-
-
Shanxi
-
Xi’an、Shanxi、中国
- The First Affiliated Hospital of Xi'an Jiaotong University
-
-
Sichuan
-
Chengdu、Sichuan、中国
- Sichuan Provincial People's Hospital
-
-
Xinjiang
-
Ürümqi、Xinjiang、中国
- People's Hospital of Xinjiang Uygur Autonomous Region
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310000
- Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University
-
Huzhou、Zhejiang、中国
- Huzhou Central Hospital
-
Ningbo、Zhejiang、中国
- The First Affiliated Hospital of Ningbo University
-
Ningbo、Zhejiang、中国
- Ningbo Medical Center Li Huili Hospital
-
Wenzhou、Zhejiang、中国
- The First Affiliated Hospital of Wenzhou Medical University
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Patients scheduled to undergo transfemoral TAVR were considered for inclusion in the trial if they met all inclusion and none of the exclusion criteria. Inclusion criteria were an indication for TAVR as judged by the local heart team; selection of the transfemoral access route and a commercially available transcatheter aortic valve; and willingness to comply with protocol specified follow-up evaluations.
Exclusion Criteria:
- Principal exclusion criteria were a vascular access site anatomy not suitable for percutaneous vascular closure and the occurrence of vascular access site complications before the TAVR procedure. Additional exclusion criteria were a known allergy or hypersensitivity to any VCD component; unstable active bleeding or bleeding diathesis or significant unman ageable anemia; absence of computed tomographic data of the access site before the procedure; systemic infection or a local infection at or near the access site; life expectancy of <6 months because of noncardiac conditions; patients who can-not adhere to or complete the investigational protocol for any reason; pregnant or nursing patients; and participation in any other interventional trial.
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器：Double Perclose device
Double Perclose device ( Perclose Proglide system, Abbott Vascular) was used for large bore arteriotomy site closure during TF-TAVR procedures |
"Preclosure" technique has emerged as a common vascular closure approach using a Perclose Proglide system (Abbott Vascular), in which sutures are deployed before dilating the arterial access site. |
|
实验性的：Single Perclose device
Single Perclose device ( Perclose Proglide system, Abbott Vascular) was used for large bore arteriotomy site closure during TF-TAVR procedures |
"Preclosure" technique has emerged as a common vascular closure approach using a Perclose Proglide system (Abbott Vascular), in which sutures are deployed before dilating the arterial access site. |
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The primary end point of the trial was the rate of access site or access-related major and minor vascular complications defined according to the Valve Academic Research Consortium-3 criteria
大体时间：The end point was assessed during index hospitalization
|
|
The end point was assessed during index hospitalization
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The rate of the primary end point at 30 days
大体时间：30 days
|
the rate of access site or access-related major and minor vascular complications at 30 days |
30 days
|
|
Components of the primary end point in-hospital and at 30 days
大体时间：30 days
|
Components of the rate of access site or access-related major and minor vascular complications at 30 days |
30 days
|
|
In-hospital and 30-day major and minor vascular complications
大体时间：30 days
|
In-hospital and 30-day major and minor vascular complications |
30 days
|
|
Unplanned vascular surgery or use of endovascular stent or stent-graft or other endovascular interventions at the puncture site
大体时间：30 days
|
Unplanned vascular surgery or use of endovascular stent or stent-graft or other endovascular interventions at the puncture site at 30 days |
30 days
|
|
in-hospital and 30-day access site- or access-related minor, major, and disabling or life- threatening bleeding; need for blood transfusion for access site or access related bleeding or vascular complications
大体时间：30 days
|
in-hospital and 30-day access site- or access-related minor, major, and disabling or life- threatening bleeding; need for blood transfusion for access site or access related bleeding or vascular complications |
30 days
|
|
Rate of VCD failure, defined as the failure of a closure device strategy to achieve hemostasis with the need for an alternative treatment (other than manual compression or adjunctive endovascular ballooning)
大体时间：30 days
|
Rate of VCD failure, defined as the failure of a closure device strategy to achieve hemostasis with the need for an alternative treatment (other than manual compression or adjunctive endovascular ballooning) at 30 days |
30 days
|
|
In-hospital and 30-day all-cause death; in-hospital and 30-day death attributed to access site- access-related complications; need and number of additional unplanned VCDs
大体时间：30 days
|
In-hospital and 30-day all-cause death; in-hospital and 30-day death attributed to access site- access-related complications; need and number of additional unplanned VCDs |
30 days
|
|
Time to hemostasis, defined as the time from VCD application to complete hemostasis
大体时间：30 days
|
Time to hemostasis, defined as the time from VCD application to complete at 30 days |
30 days
|
|
The length of postprocedural hospital stay
大体时间：30 days
|
The length of postprocedural hospital stay |
30 days
|
合作者和调查者
调查人员
- 学习椅：Jianan Wang, PhD、Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.